Abstract | BACKGROUND: METHODS: RESULTS: EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00-1.27]; P=0.047). Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P<0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P<0.001). Patients treated with exenatide or placebo had similar rates of MACE and LEA, regardless of PAD status. CONCLUSIONS: EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without PAD. There were no differences in MACE or LEA rates with exenatide versus placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.
|
Authors | Anish Badjatiya, Peter Merrill, John B Buse, Shaun G Goodman, Brian Katona, Nayyar Iqbal, Neha J Pagidipati, Naveed Sattar, Rury R Holman, Adrian F Hernandez, Robert J Mentz, Manesh R Patel, W Schuyler Jones |
Journal | Circulation. Cardiovascular interventions
(Circ Cardiovasc Interv)
Vol. 12
Issue 12
Pg. e008018
(12 2019)
ISSN: 1941-7632 [Electronic] United States |
PMID | 31752517
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- GLP1R protein, human
- Glucagon-Like Peptide-1 Receptor
- Hypoglycemic Agents
- Incretins
- Exenatide
|
Topics |
- Aged
- Cause of Death
- Diabetes Mellitus, Type 2
(diagnosis, drug therapy, mortality)
- Double-Blind Method
- Exenatide
(adverse effects, therapeutic use)
- Female
- Glucagon-Like Peptide-1 Receptor
(agonists)
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Incretins
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(mortality)
- Peripheral Arterial Disease
(diagnosis, drug therapy, mortality)
- Risk Assessment
- Risk Factors
- Stroke
(mortality)
- Time Factors
- Treatment Outcome
|